We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+55.66%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.22B
AUM Growth
+$309M
Cap. Flow
+$82.5M
Cap. Flow %
6.76%
Top 10 Hldgs %
72.94%
Holding
57
New
4
Increased
7
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$148M
2
GERN icon
Geron
GERN
+$14.8M
3
TRML
Tourmaline Bio
TRML
+$11.8M
4
ENGN icon
enGene Therapeutics
ENGN
+$6.01M
5
PHVS icon
Pharvaris
PHVS
+$5.77M

Top Sells

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$38.2M
2
ACLX
Arcellx
ACLX
+$18.1M
3
VTYX
Ventyx Biosciences
VTYX
+$14.7M
4
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$13M
5
TARS icon
Tarsus Pharmaceuticals
TARS
+$7.98M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Consumer Staples 0%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$339M 27.74%
8,418,093
+5,215,000
+163% +$148M
GRCL
2
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$95.8M 7.85%
9,546,485
-1,334,659
-12% -$6.06M
VRNA
3
DELISTED
Verona Pharma
VRNA
$84.5M 6.92%
4,249,918
– –
HRMY icon
4
Harmony Biosciences
HRMY
$2.07B
$84.2M 6.89%
2,606,247
– –
ALXO icon
5
ALX Oncology
ALXO
$268M
$62.8M 5.14%
4,220,048
– –
AVDL
6
DELISTED
Avadel Pharmaceuticals
AVDL
$57.8M 4.74%
4,096,428
– –
GERN icon
7
Geron
GERN
$930M
$50.9M 4.17%
24,143,681
+7,619,047
+46% +$14.8M
TERN
8
DELISTED
Terns Pharmaceuticals
TERN
$43.2M 3.54%
6,657,992
– –
VRDN icon
9
Viridian Therapeutics
VRDN
$2.15B
$36.6M 2.99%
1,678,207
– –
TARS icon
10
Tarsus Pharmaceuticals
TARS
$2.57B
$36.1M 2.96%
1,784,006
-478,194
-21% -$7.98M
ICVX
11
DELISTED
Icosavax, Inc. Common Stock
ICVX
$26.9M 2.2%
1,704,568
– –
OLMA icon
12
Olema Pharmaceuticals
OLMA
$1.01B
$26.3M 2.15%
1,873,704
– –
ATXS
13
DELISTED
Astria Therapeutics
ATXS
$19.1M 1.56%
2,482,727
+801,528
+48% +$4.43M
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$15.6M 1.28%
819,275
-95,638
-10% -$1.33M
TRML
15
DELISTED
Tourmaline Bio
TRML
$15.5M 1.27%
+591,882
New +$11.8M
CMPS
16
Compass Pathways
CMPS
$1.46B
$14.1M 1.15%
1,608,000
– –
DYN icon
17
Dyne Therapeutics
DYN
$4.28B
$13.8M 1.13%
1,035,136
– –
COGT icon
18
Cogent Biosciences
COGT
$6.95B
$13.2M 1.08%
2,244,941
– –
VSTM icon
19
Verastem
VSTM
$547M
$12.5M 1.03%
1,538,461
– –
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.88B
$12.5M 1.02%
350,000
– –
IOBT
21
DELISTED
IO Biotech
IOBT
$11.6M 0.95%
6,173,439
– –
ZLAB icon
22
Zai Lab
ZLAB
$2.1B
$11.3M 0.92%
411,677
-42,929
-9% -$1.13M
APGE icon
23
Apogee Therapeutics
APGE
$10.1B
$11.2M 0.92%
400,000
– –
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$10.5M 0.86%
856,008
– –
GTH
25
DELISTED
Genetron Holdings Limited ADS
GTH
$9.97M 0.82%
2,708,056
-2
-0% -$7
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Vivo Capital held 57 positions worth $1.22B, up 34% from $913M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Vivo Capital deployed $82.5M of net new capital in Q4 2023, opening 4 new positions and adding to 7 existing holdings. Its largest new stake was Tourmaline Bio: 591,882 shares worth $15.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Consumer Staples and Materials.

On the sell side, the largest reduction was RayzeBio, Inc. Common Stock, an estimated $13M trimmed.

  • Vivo Capital's largest Q4 2023 buy was Tourmaline Bio: 591,882 shares worth $15.5M.
  • Vivo Capital added most to Soleno Therapeutics in Q4 2023, an estimated $148M increase.
  • Vivo Capital's biggest Q4 2023 reduction was RayzeBio, Inc. Common Stock, cutting an estimated $13M.
  • Vivo Capital fully exited Sinovac Biotech, Ltd in Q4 2023, selling an estimated $38.2M.
  • Vivo Capital's ten largest holdings make up 73% of its $1.22B portfolio in Q4 2023.
  • Vivo Capital opened 4 new positions and closed 10 in Q4 2023.
  • Vivo Capital's portfolio value rose 34% quarter-over-quarter to $1.22B.

Based on Vivo Capital's 13F filing for Q4 2023, filed 7 Feb 2024.